ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Enzon Pharmaceuticals has hired a financial adviser to help it consider selling all or part of the company. The move comes after investor Carl Icahn, who owns just over 13% of the firm, indicated in a late-November regulatory filing that he wishes to discuss the company’s direction with its management. Enzon sold its specialty drug business in 2010 and has since focused on using its PEGylation linker technology and mRNA-targeting agents to develop cancer therapeutics. Last week, however, it suspended clinical development of its androgen receptor program.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X